Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery

21 September 2026 · By · Wire by Fusion42

Published

21 September 2026

Topic

opportunities

◆ Sectors

Drug Discovery

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 21 September 2026 · Fusion42 review

AbbVie and Iambic have announced a multi-year collaboration leveraging Iambic's AI-driven molecular superintelligence platform to accelerate the discovery and development of small molecule therapies in immunology, neuroscience, and oncology.

This Wire brief sits within Fusion42's coverage of Drug Discovery, and 3 sources have reported it between 21 Sep 2026 and 22 Sep 2026.

◆ ◆ The Wire takeaway

You can now plan to integrate advanced AI tools into drug discovery programs, as AbbVie’s deal with Iambic shows big pharma is betting on AI to speed molecule design and improve success rates in tough therapeutic areas.

◆ Coverage

3 sources · first reported 21 Sep 2026 · latest 22 Sep 2026

◆ Related on Wire

◆ Topics

Drug Discoveryaidrug-discoverycollaborationimmunologyoncology